Oxidative DNA damage in chronic renal failure patients

Nephrology Dialysis Transplantation

Volumn 25, Issue 3, 2010, Pages 879-885

  Stoyanova, Elitsa ^a   Sandoval, Silvia Berenice ^a   Zúñiga, Liliana Andrea ^a   El Yamani, Naouale ^a   Coll, Elisabet ^b   Pastor, Susana ^a,c   Reyes, Joselyn ^b   Andrés, Enrique ^b   Ballarin, José ^b   Xamena, Noel ^a,c   Marcos, Ricard ^a,c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b FUNDACIÓ PUIGVERT   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Comet assay; CRF; Haemodialysis treatment; Oxidative damage; Uraemic state

Indexed keywords

CREATININE; DNA BASE; DNA GLYCOSYLTRANSFERASE; ENDONUCLEASE; ENDONUCLEASE III; FORMAMIDEPYRIMIDINE DNA GLYCOSILASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; COMET ASSAY; CREATININE BLOOD LEVEL; DNA DAMAGE; FEMALE; GENETIC DAMAGE; GENOMICS; HEMODIALYSIS PATIENT; HEREDITY; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; UREMIA;

AGED; COMET ASSAY; CREATININE; CROSS-SECTIONAL STUDIES; DNA; DNA DAMAGE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; RENAL DIALYSIS; TIME FACTORS;

EID: 77649197464     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp575     Document Type: Article

References (46)

1. Collins AR. Investigating oxidative DNA damage and its repair using the comet assay. Mutat Res 2009; 681: 24-32
2. Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 2004; 24: 469-473
3. Galle J. Oxidative stress in chronic renal failure. Nephrol Dial Transplant 2001; 16: 2135-2137
4. Palleschi S, De Angelis S, Diana L, et al. Reliability of oxidative stress biomarkers in hemodialysis patients: a comparative study. Clin Chem Lab Med 2007; 45: 1211-1218
5. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799-805
6. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-99
7. Teschner M, Garte C, Ruckle-Lanz H, et al. Incidence and spectrum of malignant disease among dialysis patients in north Bavaria. Dtsch Med Wochenschr 2002; 127: 2497-2502
8. Weiner DE. Causes and consequences of chronic kidney disease: implications for managed health care. J Manag Care Pharm 2007; 13 (3 Suppl): S1-S9
9. Durak I, Kacmaz M, Elgun S, et al. Oxidative stress in patients with chronic renal failure: effects of hemodialysis. Med Princ Pract 2004; 13: 84-87
10. Roselaar SE, Nazhat NB, Winyard PG, et al. Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney Int 1995; 48: 199-206
11. Mimic-Oka J, Simic T, Djukanovic L, et al. Alteration in plasma an-tioxidant capacity in various degrees of chronic renal failure. Clin Nephrol 1999; 51: 233-241
12. Muller C, Eisenbrand G, Gradinger M, et al. Effects of hemodialysis, dialyser type and iron infusion on oxidative stress in uremic patients. Free Radic Res 2004; 38: 1093-1100
13. Schinzel R, Munch G, Heidland A, et al. Advanced glycation end products in end-stage renal disease and their removal. Nephron 2001; 87: 295-303 (Pubitemid 32260829)
14. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-9897
15. Witko-Sarsat V, Nguyen-Khoa T, Jungers P, et al. Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia. Nephrol Dial Transplant 1999; 1476-1478
16. Handelman GJ, Walter MF, Adhikarla R, et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001; 59: 1960-1966
17. Lucchi L, Iannone A, Bergamini S, et al. Comparison between hydro-peroxides and malondialdehyde as markers of acute oxidative injury during hemodialysis. Artif Organs 2005; 29: 832-837
18. Gedik CM, Collins A. ESCODD (European Standards Committee on Oxidative DNA Damage). Establishing the background level of base oxidation in human lymphocyte DNA: results of an interlaboratory validation study. FASEB J 2005; 19: 82-84
19. Singh NP, McCoy MT, Tice RR, et al. A simple technique for quan-titation of low levels of DNA damage in individual cells. Exp Cell Res 1988; 175: 184-191
20. Lovell DP, Omori T. Statistical issues in the use of the comet assay. Mutagenesis 2008; 23: 171-182
21. Dusinska M, Collins AR. The comet assay in human biomonitoring: gene-environment interactions. Mutagenesis 2008; 23: 191-205
22. Moller P. Assessment of reference values for DNA damage detected by the comet assay in human blood cell DNA. Mutation Res 2006; 612: 84-104
23. Stopper H, Boullay F, Heidland A, et al. Comet-assay analysis identifies genomic damage in lymphocytes of uremic patients. Am J Kidney Dis 2001; 38: 296-301
24. Pernice F, Floccari F, Nostro L, et al. Oxidative stress, sister chromatid exchanges and apoptosis in the pathogenesis of lymphocytopenia in ESRD patients. J Nephrol 2006; 19: 613-620
25. Schupp N, Stopper H, Rutkowski P, et al. Effect of different hemodi-alysis regimens on genomic damage in end-stage renal failure. Semin Nephrol 2006; 26: 28-32 (Pubitemid 43075507)
26. Stopper H, Meysen T, Böckenförde A, et al. Increased genomic damage in lymphocytes of patients before and after long-term maintenance hemodialysis therapy. Am J Kidney Dis 1999; 34: 433-437
27. Kobras K, Schupp N, Nehrlich K, et al. Relation between different treatment modalities and genomic damage of end-stage renal failure patients. Kidney Blood Press Res 2006; 29: 10-17 (Pubitemid 43875167)
28. Kan E, Undeger U, Bali M, et al. Assessment of DNA strand breakage by the alkaline COMET assay in dialysis patients and the role of vitamin E supplementation. Mutat Res 2002; 520: 151-159
29. Bagatini PB, Palazzo RP, Rodrigues MT, et al. Induction and removal of DNA damage in blood leukocytes of patients with type 2 diabetes mellitus undergoing hemodialysis. Mutat Res 2008; 657: 111-115
30. Domenici FA, Vannucchi MT, Jordao AA Jr, et al. DNA oxidative damage in patients with dialysis treatment. Ren Fail 2005; 27: 689-694
31. Tarng DC. Wen Chen T, et al. Increased oxidative damage to peripheral blood leukocyte DNA in chronic peritoneal dialysis patients. J Am Soc Nephrol 2002; 13: 1321-1330
32. Herman M, Ori Y, Chagnac A, et al. Spontaneous DNA repair increases during hemodialysis. Nephron Clin Pract 2008; 108: 188-193
33. Zevin D, Malachi T, Gafter U, et al. Impaired DNA repair in patients with end-stage renal disease and its improvement with hemodialysis. Miner Electrolyte Metab 1991; 17: 303-306
34. Malachi T, Zevin D, Gafter U, et al. DNA repair and recovery of RNA synthesis in uremic patients. Kidney Int 1993; 44: 385-389
35. Vamvakas S, Bahner U, Becker P, et al. Impairment of DNA repair in the course of long-term hemodialysis and under cyclosporine immu-nosuppression after renal transplantation. Transplant Proc 1996; 28: 3468-3473
36. Liu CS, Ko LY, Lim PS, et al. Biomarkers of DNA damage in patients with end-stage renal disease: mitochondrial DNA mutation in hair follicles. Nephrol Dial Transplant 2001; 16: 561-565
37. Wei YH, Lee HC. Oxidative stress, mitochondrial DNA mutation, and impairment of antioxidant enzymes in aging. Exp Biol Med (Maywood) 2002; 227: 671-682
38. Boxall MC, Goodship TH, Brown AL, et al. Telomere shortening and haemodialysis. Blood Purif 2006; 24: 185-189
39. Hagmar L, Brøgger A, Hansteen IL, et al. Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res 1987; 54: 2919-2922
40. Botto N, Rizza A, Colombo MG, et al. Evidence for DNA damage in patients with coronary artery disease. Mutat Res 2001; 27: 23-30
41. Martinet W, Knaapen MW, De Meyer GR, et al. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation 2002; 106: 927-932
42. Andreassi MG. Coronary atherosclerosis and somatic mutations: an overview of the contributive factors for oxidative DNA damage. Mu-tat Res 2003; 543: 67-86
43. Vamvakas S, Bahner U, Heidland A. Cancer in end-stage renal disease: potential factors involved-editorial. Am J Nephrol 1998; 18: 89-95
44. Sebekova K, Wagner Z, Schupp N, et al. Genomic damage and malignancy in end-stage renal failure: do advanced glycation end products contribute?. Kidney Blood Press Res 2007; 30: 56-66
45. Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol 2004; 15S77-S80
46. Andreassi MG. DNA damage, vascular senescence and atherosclerosis. J Mol Med 2008; 86: 1033-1043